Inspire Medical Systems Reaches over 1,000 Implants for the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Inspire Medical Systems Reaches over 1,000 Implants for the Treatment of Obstructive Sleep Apnea

Strong demand year-to-date driving revenues already exceeding sales for full-year 2015

Inspire therapy is currently available at more than 100 leading medical centers across the U.S. and Europe

Company Named 33 rd Fastest-Growing U.S. Private Company on Inc. 5000

MINNEAPOLIS, Aug. 22, 2016 (GLOBE NEWSWIRE) --   Inspire Medical Systems , Inc., a medical technology company that has developed and is commercializing a neurostimulation platform for the treatment of obstructive sleep apnea (OSA), today announced that the Company’s Inspire therapy has now been implanted in over 1,000 patients in the U.S. and Europe. 

Inspire therapy is an FDA-approved treatment for people with moderate to severe OSA who are unable to use continuous positive airway pressure (CPAP). In contrast to CPAP, the Inspire device works inside the body and with a patient’s natural breathing process. Inspire also previously received CE Mark, which allows for commercial use of the device in Europe. 

The growing demand for Inspire therapy has generated revenues year-to-date that have already exceeded sales for the full-year 2015.  Moreover, in recognition of the Company’s rapid revenue growth through calendar year 2015, Inspire was recently named by Inc. magazine as the 33 rd fastest-growing private company in America on the 2016 Inc. 5000 list.  The rankings are based on the percentage of revenue growth over a four-year period.

In support of driving further growth of Inspire, important clinical data was recently presented at the 30 th Annual SLEEP Meeting in Denver, Colorado.  Among several oral/poster presentations, three presentations included additional clinical evidence for patients implanted with Inspire and one that included further long-term data from the S timulation T herapy for A pnea R eduction (STAR) trial.  Each study supported the fact that Inspire therapy is an adjustable, titratable medical device that decreases the burden of moderate to severe OSA in those patients unable to get consistent benefit from CPAP.  In addition, Inspire has been the subject of over 20 peer-reviewed articles.

“We are pleased to reach this important milestone in the adoption of Inspire,” said Tim Herbert, President and CEO of Inspire Medical Systems, Inc.  “We expect that the growing number of positive clinical experiences with our therapy and the recently announced extended data from the STAR Trial with outcomes through 36 and 42 months will drive further demand for our therapy.  The increasing demand for Inspire is driving significant revenue growth, as our year-to-date sales in 2016 are now higher than our full-year revenues for 2015.”

OSA is a large market that affects approximately 18 million people in the U.S. It is important for affected individuals to identify an effective treatment option, as untreated OSA can have devastating effects on heart and brain health, impair quality of life and increase accident risk. 

Inspire therapy is currently available in more than 100 leading medical centers across the U.S. and Europe as a result of continued excellent clinical data and growing physician experience. 

About Inspire Therapy Inspire Upper Airway Stimulation therapy is an FDA-approved treatment for some people with moderate to severe OSA who are unable to tolerate or get relief from continuous positive airway pressure (CPAP). In contrast to CPAP, Inspire therapy is implanted inside the body and works with a patient's natural breathing process. Controlled by the patient sleep remote, the system includes a breathing sensor and a stimulation lead powered by a small battery. During sleep, the system senses breathing patterns and delivers mild stimulation to the tongue and other soft tissues of the throat to keep the airway open. Inspire therapy is currently available at more than 100 leading medical centers across the United States and Europe. 

About Inspire Medical Systems, Inc. Inspire Medical Systems , Inc., based in Minneapolis, Minn., was incorporated with the purpose of developing a safe, effective and well-accepted therapy to help those OSA patients who are unable to tolerate or get relief from CPAP. Inspire therapy is the world’s first implantable FDA-approved neurostimulation system for the treatment of OSA. The Company is privately held and investors include Aperture Venture Partners, GDN Holdings, Johnson & Johnson, Kleiner Perkins Caufield & Byers, Medtronic, OrbiMed Advisors, Synergy Life Science Partners, TGap Ventures and US Venture Partners.

For more information, visit  www.InspireSleep.com .

Investor Contact: Rick Buchholz rickbuchholz@inspiresleep.com Media Contact: Howard Green howardgreen@inspiresleep.com 651-357-3616

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 136

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
Shenzhen Three-Way Summit Puts Stability to the Test

Updated Category News Views 191

Three nuclear powers sharing a room in Shenzhen is the sort of headline that makes every risk desk sit upright, even when the paperwork remains thin. CGTN reports that Chinese President Xi Jinping, Russian President Vladimir Putin and U.S. President Donald Trump met on November 19, 2026, in an unprecedented trilateral summit and issued a Declaration toward Peace. That is...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 96

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 79

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading
Lieda Shadwick’s Career Education Work Earns 2026 Honor

Updated Category News Views 76

Twenty-six years in classrooms is not the sort of accomplishment that needs fireworks to carry weight. Lieda A. Shadwick’s recognition as The Inner Circle’s 2026 Educator of the Year points to a career built around a stubbornly important idea: students need more than academic vocabulary if they are going to navigate work, leadership, and business with any confidence....

Continue Reading
Ductless Mini-Splits Put HVAC Efficiency Into Focus

Updated Category News Views 46

Ductless mini-splits have slipped from contractor jargon into a serious conversation about how homes and smaller buildings are heated and cooled. That is the worthwhile backdrop for a HelloNation article featuring HVAC expert Natasha Adams. The source notes are lean—really lean—and do not spell out her specific guidance, product comparisons, efficiency figures,...

Continue Reading
Fermi Board Fight Tests Texas Governance Standards Again

Updated Category News Views 60

A boardroom rulebook is supposed to restrain power, not become a trapdoor under shareholders’ feet. That is the ugly governance question hanging over Fermi after the Texas Business Court dismissed Toby Neugebauer’s challenge to the company’s 70% supermajority bylaw. Neugebauer, Fermi’s co-founder and largest shareholder, says he will appeal. Frankly, he has every...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 134

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 101

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 105

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Investigation into iTeos Therapeutics Acquisition

Updated Category News Views 182

Investigation Overview of iTeos Therapeutics, Inc. Rowley Law PLLC is currently delving into possible violations of securities laws involving iTeos Therapeutics, Inc. (NASDAQ: ITOS) and its board of directors regarding the proposed acquisition by Concentra Biosciences, LLC. This acquisition aims to provide stockholders with $10.047 for each share they hold, accompanied by...

Continue Reading
Ares Management Joins S&P 500; Changes in SmallCap 600

Updated Category News Views 483

Ares Management Join the S&P 500 In an exciting development for investors, Ares Management (NYSE: ARES) will be joining the S&P 500 index shortly. This news comes as Kellanova (NYSE: K) has announced its acquisition by Mars Inc., which has precipitated the need for these changes in the index. Ares Management is making a mark in the financial sector and its inclusion...

Continue Reading
Berkshire Hathaway's Q3 Earnings Report: Key Insights Revealed

Updated Category News Views 113

Berkshire Hathaway's Underwhelming Third Quarter Performance Berkshire Hathaway's recent third-quarter earnings report has raised eyebrows as the results fell short of analyst predictions. The earnings per share (EPS) came in at $4.68, whereas consensus estimates were looking for $4.89. Analysts have pointed to several factors influencing this underperformance. Insurance...

Continue Reading
Multitude SE Reports 34.5% EBIT Growth in 2024

Updated Category News Views 101

Multitude SE Reports Strong Growth in 2024 Key takeaways: The company continues to perform well, maintaining a robust cash position. Group revenue has risen by 17.0%, reaching EUR 128.8 million. All business units are reporting at least double-digit revenue growth. On track to meet EBIT guidance of EUR 67.5 million (+50%) for 2024. Multitude SE, a leading European FinTech...

Continue Reading
Discover How Cboe Global Markets Has Grown Over a Decade

Updated Category News Views 241

Understanding the Growth of Cboe Global Markets Cboe Global Markets has displayed remarkable performance in the stock market over the past decade. Specifically, the company has outperformed the market by an average of 2.96% annually, resulting in a substantial annual return of approximately 14.72%. Presently, its market capitalization stands at around $26.52 billion,...

Continue Reading